Intratumoral Cancer Therapies Market

Intratumoral cancer therapies generated USD 2.12 billion in 2025 under a broad modality definition that includes locally delivered products, attributable administration and development-service revenue. Revenue is estimated at USD 2.37 billion in 2026 and projected at USD 5.68 billion in 2034, representing an 11.6% CAGR.

The modality combines a drug placed directly into a tumor with the clinical work needed to select accessible lesions, prepare the material and deliver repeat injections. Amgen's Imlygic has a U.S. melanoma label for cutaneous, subcutaneous and nodal lesions, while Replimune's Tudriqev received an accelerated U.S. melanoma approval in August 2026. Those approvals have different populations and cannot be used interchangeably. Japan separately authorized Oncolys BioPharma's Telomelysin for a narrowly defined esophageal-cancer population in June 2026.

Revenue coverage is broader than sales of licensed viral medicines alone. The publisher's USD 2.12 billion 2025 figure includes attributable intratumoral drug supply, injection and image-guidance procedures, trial material and eligible development contracts, without treating the full sales of companion intravenous immunotherapies as intratumoral revenue. Products injected intravenously but merely expressing a payload inside tumors are outside the strict local-delivery definition. This distinction excludes Akamis Bio's systemically delivered NG-350A while preserving local injection programs such as Candel's CAN-2409.

Clinical uptake depends on the number and location of lesions that can be safely reached. Surface melanoma deposits are comparatively straightforward to inject, whereas lung, pancreatic, esophageal and prostate tumors may require imaging, endoscopy or specialized procedural teams. Replimune's IGNYTE study evaluated 91 patients with non-injected lesions for its primary efficacy analysis and reported a 24.2% response rate. This evidence supports the approved post-PD-1 melanoma setting but does not establish a general approval for all solid tumors.

Development activity also includes Candel's 2026 CAN-2409 follow-up and new local viral trials. Candel reported survival follow-up for intratumoral CAN-2409 in lung cancer in March 2026; BioInvent and Transgene presented early BT-001 data at ESMO 2025; and ImmVirX announced a February 2026 clinical supply agreement for intratumoral IVX055 with tislelizumab. Each program carries trial-stage uncertainty, so prospective clinical revenue is separated from product sales. The forecast assumes more eligible treatment centers, improved lesion targeting and selective approvals rather than blanket adoption across oncology.

Source: FDA Imlygic; FDA Tudriqev; Candel trial.

This study measures global revenue attributable to medicines deliberately administered into tumor tissue and to directly linked delivery, development and clinical-service components. It differentiates approved product supply from trial-stage activity and never treats an investigational candidate as an authorized treatment.

Drivers Impact Analysis*

Restraints Impact Analysis*

*CAGR contribution shows the percentage points each factor adds to or removes from the 11.6% CAGR for 2026–2034; driver contributions less restraint contributions equal the market CAGR. Period columns rate the strength of each factor in that window.

U.S. approvals create distinct commercial melanoma treatment pathways

The FDA's August 2026 accelerated approval of Tudriqev with nivolumab added an intratumoral option after progression on PD-1-based therapy. Replimune reported a 24.2% response rate among 91 efficacy-evaluable patients with noninjected lesions, and the median response duration reached 14.1 months. This label differs from Amgen's established Imlygic use for recurrent melanoma lesions after surgery. Oncologists must verify treatment history, lesion accessibility and product-specific safety before selecting either option. Commercial uptake therefore depends on referral networks and appropriate patient identification, not simply on melanoma prevalence.

Image-guided access expands the range of injectable solid tumors

Lesions in the pancreas, prostate, lung or esophagus often cannot be reached by direct palpation, unlike superficial melanoma nodules. Candel's CAN-2409 has been studied through local delivery in prostate, lung and pancreatic cancers, while Oncolys BioPharma has evaluated Telomelysin in esophageal tumors. These protocols require different procedural teams, imaging support and monitoring. As hospitals integrate oncology with interventional radiology, endoscopy and urology, more eligible patients can receive local injections. The additional procedural cost must remain distinct from the drug's manufacturer selling price.

Intratumoral immune activation can complement systemic checkpoint blockade

BioInvent and Transgene presented BT-001 data in October 2025 after administering the oncolytic virus locally alongside intravenous pembrolizumab. Their early observations included changes in injected and noninjected lesions, but the phase 1 study was not a registration trial. ImmVirX announced a February 2026 plan to study intratumoral IVX055 with tislelizumab in Australia. Such combinations aim to modify the tumor microenvironment while retaining systemic immune surveillance. They also create attribution challenges: the value of separately administered checkpoint antibodies must not be recorded again as intratumoral product revenue.

Narrow indications and trial obligations restrain addressable demand

Regulatory authorization is not transferable across tumor sites, prior-treatment settings or countries. The European Medicines Agency limits Imlygic to selected unresectable melanoma without visceral disease, while the U.S. Tudriqev indication requires progression after PD-1 treatment and a nivolumab combination. Replimune must verify clinical benefit in post-approval studies because accelerated authorization relied on response outcomes. Developers such as Candel and Lokon Pharma remain in clinical development despite encouraging trial signals. These restrictions reduce immediate eligible volumes and require careful communication to treatment centers and payers.

Complex handling and repeat injections increase delivery costs

Intratumoral viral products can require frozen storage, trained staff, infection-control procedures and lesion reassessment at each visit. The FDA's Tudriqev label describes injections every two weeks for eight doses, with volume based on the largest tumor dimension and a maximum across lesions. Imlygic also requires repeated lesion-directed treatment under specialist oncology supervision according to its FDA label. Unlike a routine oral oncology prescription, the hospital must coordinate pharmacy preparation with procedural appointments and safe disposal. Regional capacity differences can delay adoption even where a medicine has regulatory approval and reimbursement.

Source: FDA Tudriqev and Imlygic approvals; EMA Imlygic EPAR; Replimune IGNYTE disclosures; BioInvent and Transgene BT-001 study; ImmVirX clinical collaboration; Candel CAN-2409.

Approved viral products are moving beyond one melanoma treatment line

Imlygic established a local viral treatment pathway for selected melanoma lesions years before the 2026 approval of Tudriqev. The newer therapy addresses adults whose advanced cutaneous melanoma progressed during PD-1-based treatment and is administered with intravenous nivolumab. Replimune began U.S. commercial availability in October 2026, with an access-support program for treatment centers. These differences encourage oncology networks to develop separate clinical protocols rather than a single generic intratumoral pathway. The pace of uptake will depend on confirmatory data, reimbursement decisions and the number of eligible injectable lesions.

Oncolytic viruses are being engineered to carry immune payloads

BT-001 uses an oncolytic platform to express an anti-CTLA-4 antibody and GM-CSF within injected tumors, according to BioInvent's clinical-program description. Its goal is to concentrate immune stimulation locally while limiting systemic exposure. Replimune's approved virus also encodes GM-CSF and a fusogenic protein, but the molecules and evidence packages are different. Local cytokine and antibody delivery remains an active development strategy because conventional systemic immune therapies can cause widespread toxicity. Clinical-stage responses cannot be treated as proof of future marketing authorization or broad efficacy.

Tumor-specific gene transfer is being studied with standard treatment

Candel's CAN-2409 is a replication-defective adenovirus that transfers a thymidine-kinase gene into tumors and is paired with an oral prodrug. In May 2025 the company presented phase 3 localized prostate cancer results showing a disease-free survival hazard ratio of 0.70 against control. CAN-2409 remained investigational when those phase 3 results were presented in 2025. Separate lung and pancreatic studies suggest additional development routes but do not establish efficacy in every indication. Local delivery may become part of multimodal treatment rather than replace surgery, radiation or systemic medicines.

Japanese authorization highlights regional differences in viral therapy access

Oncolys BioPharma announced Japanese marketing approval for Telomelysin Injection in June 2026 for esophageal cancer patients who were not candidates for specified curative treatments. The company expected commercialization through FUJIFILM Toyama Chemical following national price listing. That approval does not confer U.S. or European authorization. Japan's specialist endoscopy infrastructure offers a different local-delivery pathway from U.S. melanoma clinics. Revenue forecasts must therefore separate Japan-specific commercial milestones and supply arrangements from unapproved indications under investigation elsewhere.

Development partnerships are financing trials before commercial sales

ImmVirX and BeOne Medicines announced a February 2026 supply agreement for IVX055 with tislelizumab in an Australian phase 1 study. BioInvent and Transgene share development of BT-001, while Lokon Pharma has partnered on clinical testing of LOAd703 with an anti-PD-1 agent. Such agreements can generate manufacturing, milestone or research-service receipts before an investigational therapy reaches pharmacy shelves. This revenue separation is necessary when interpreting the USD 2.12 billion modality base. Clinical-stage organizations should be profiled for technology and trial activity without implying that their candidates are already approved medicines.

Intratumoral therapy spans approved local viral products and investigational gene-transfer or immune-stimulatory platforms. Clinical outcomes depend on disease setting, accessible lesions, companion treatments and trial design; a response rate from one indication cannot be transferred to another cancer.

Amgen's Imlygic is an engineered herpes simplex virus injected into melanoma lesions. Its U.S. indication covers local treatment of unresectable cutaneous, subcutaneous and nodal lesions after initial surgery, while the European label specifies regional or limited distant spread without visceral involvement. Treatment requires specialist administration and monitoring for viral exposure or herpetic complications. These requirements distinguish a locally replicating virus from a conventional oral targeted drug. Clinical benefit should be discussed within the approved label rather than extended to unrelated cancers or untested combinations.

Replimune's Tudriqev received U.S. accelerated approval in August 2026 with nivolumab for adults whose unresectable advanced cutaneous melanoma progressed on PD-1 therapy. The FDA reported a 24.2% response rate in 91 efficacy-evaluable patients and a median response duration of 14.1 months. The product became commercially available in October, after the 2025 base year. Confirmatory studies remain a condition of the FDA's August 2026 accelerated authorization. Its post-checkpoint setting and dosing protocol should not be conflated with Imlygic's earlier recurrent-melanoma indication.

Candel's CAN-2409 transfers a gene encoding herpes simplex virus thymidine kinase, allowing the oral prodrug valacyclovir to generate local cytotoxic activity. In 2025, phase 3 localized prostate cancer results showed a hazard ratio of 0.70 for disease-free survival compared with control. Separate lung and pancreatic studies address different patients and endpoints. The agent remains investigational, and clinical findings cannot be presented as a marketing approval. Research expenditure and trial supply are distinct from finished-drug commercial sales.

BioInvent and Transgene's BT-001 delivers an anti-CTLA-4 payload locally using an oncolytic vector, whereas ImmVirX's IVX055 is planned for combination study with intravenous tislelizumab. Lokon Pharma is testing LOAd703 in pancreatic cancer. These programs represent diverse ways of altering the tumor microenvironment, but their evidence is preliminary and indication-specific. A combination partner administered intravenously remains outside the intratumoral product value, even when trial outcomes depend on both agents. Development-stage contributions are recorded under separate collaboration and trial categories.

Four mutually exclusive therapeutic mechanisms define the modality split. Oncolytic viruses account for the largest 2025 allocation because Imlygic is marketed and newer viral candidates dominate the clinical evidence base. Gene-transfer approaches, locally delivered immune modulators and direct cytotoxic injections form the remaining categories; each therapy is assigned to its principal mechanism rather than counted twice.

Technology mix should become more diverse as gene-transfer candidates progress through randomized testing and regional regulators assess additional oncolytic indications. However, approval depends on tumor-specific evidence and an acceptable safety profile, not the novelty of a platform. Forecast revenue therefore recognizes only defensible commercial pathways while identifying early-stage partnerships and clinical work as separate components.

Indications are allocated by the malignancy actually treated, not by the sponsor's full oncology portfolio. Melanoma remains the largest base-year application because accessible skin and nodal lesions are amenable to repeated injection. Prostate, lung and gastrointestinal tumors depend more heavily on specialized procedural access and usually remain investigational for the local products discussed.

Other solid tumors include carefully defined clinical-stage programs in sarcoma, brain tumors and additional gastrointestinal sites. Each patient is classified once by the primary tumor under treatment. Changes in indication share depend on confirmatory outcomes, hospital capacity and national reimbursement, so an early response signal is not automatically converted into forecast commercial market share.

Revenue components separate the value of a supplied local medicine from hospital procedural activity and from development-stage transactions. The publisher's broad modality valuation cannot be interpreted as finished-drug net sales alone. Every receipt is allocated to one component at the transaction level to avoid double-counting the same vial, injection visit or clinical supply agreement.

As approved products expand, the commercial supply component could rise, although reimbursement structures may transfer a larger share of value to treatment facilities. The model treats product, service and development receipts as exclusive categories. Differences in gross versus net revenue recognition are resolved at the transaction boundary instead of being presented as additional market demand.

The delivery dimension classifies the actual technique used to reach a tumor, independent of the medicine's biological mechanism. Direct palpation is most common for superficial melanoma lesions treated with Imlygic. Ultrasound, cross-sectional imaging and endoscopy extend access to deeper sites but add training and procedural costs. Every treatment course is assigned to its principal guidance method.

Technique shares are expected to shift as deeper solid-tumor indications advance, but patient safety and lesion accessibility will remain decisive. The same biological agent may be administered using different guidance in separate trials; the market therefore records actual delivery activity rather than treating all possible routes as distinct sales opportunities. These categories total 100% of the modeled 2025 base.

Regional demand reflects melanoma incidence, access to specialist tumor injection, local regulatory authorization and the ability to finance development-stage programs. North America leads the modeled 2025 allocation, followed by Europe and Asia-Pacific. Shares are exclusive geographic revenue allocations rather than manufacturer disclosures.

The intratumoral cancer therapy field combines a small marketed-product base with developers working on locally injected viral and gene-transfer candidates. Commercial ownership and clinical collaborations must be distinguished: an investigational partner is a relevant competitor but does not yet generate approved product sales.

Marketed-product competition differs sharply between the FDA-approved Imlygic and Tudriqev indications. Imlygic addresses selected recurrent melanoma lesions, while Tudriqev is paired with nivolumab after prior PD-1 therapy. Their different eligibility criteria, safety requirements and dosing schedules reduce direct substitution. Replimune's October 2026 U.S. availability announcement also indicates the importance of access-support services. The commercial outlook should not assume that all melanoma centers can immediately adopt the new therapy or that its label extends to every solid tumor.

Oncolys BioPharma offers a geographically distinct example. Japanese approval of Telomelysin in esophageal cancer is relevant to specialist endoscopy, whereas the U.S. melanoma products typically involve accessible skin or nodal lesions. The company described a commercialization partnership and planned national price listing before launch. The opportunity depends on local patient eligibility and procedural capacity rather than the total global esophageal cancer population. No overseas authorization is inferred from the Japanese decision.

Candel, BioInvent, Transgene, ImmVirX and Lokon Pharma compete for development partners, clinical sites and eventual regulatory opportunities. CAN-2409 uses gene transfer with a prodrug, BT-001 carries local immune payloads in an oncolytic virus, and IVX055 is being prepared for an Australian combination study. These mechanisms are not equivalent and may address different cancers. Early-stage data should inform research positioning without being converted into unsupported product-market shares.

Companies with systemic-only oncology programs are excluded even when their medicines are administered with a local injection. Intravenous checkpoint antibodies are combination partners rather than intratumoral products, and intravenous vectors that express proteins within tumors are not counted as locally injected agents. This ownership and delivery discipline prevents unrelated large-cap pharmaceutical revenue from dominating a market that is defined by the route of administration and the specific therapy supplied.

• Amgen Inc.
• Replimune Group Inc.
• Candel Therapeutics Inc.
• Transgene SA
• BioInvent International AB
• ImmVirX Pty Ltd
• Oncolys BioPharma Inc.
• Lokon Pharma AB

The global intratumoral cancer therapies market is forecast to reach USD 5.68 billion in 2034 from an estimated USD 2.37 billion in 2026, reflecting 11.6% annualized growth. Adoption will depend on indication-specific approvals, lesion accessibility, treatment-center capacity and the ability to distinguish local therapy revenue from companion systemic medicines.

North America should retain the largest revenue allocation because U.S. commercial access includes both Imlygic and the newly authorized Tudriqev regimen. Growth may come from qualifying patients whose melanoma progressed on checkpoint therapy, but the FDA's confirmatory requirement remains a significant clinical uncertainty. Replimune's initial treatment-center rollout in October 2026 provides a starting point for adoption, not a guarantee of uniform national availability. Payer decisions and viral-handling capabilities will influence the pace of prescribing.

Europe has an established regulatory pathway for Imlygic, while development organizations such as BioInvent and Transgene are testing new local viral mechanisms. The region's national reimbursement differences and stringent patient-selection requirements are likely to moderate short-term commercialization. Japan's Telomelysin authorization offers a separate Asian growth route centered on esophageal cancer and specialist endoscopy. Australia contributes trial infrastructure for IVX055. The forecast does not transfer approvals across jurisdictions or count investigational programs as marketed products before authorization.

Clinical development of CAN-2409, BT-001 and IVX055 could expand future indications. Candel's CAN-2409 has randomized prostate-cancer data and additional lung-cancer follow-up, while BT-001 and IVX055 represent different approaches to concentrating immune effects inside tumors. Future pivotal trials could support new indications, but early response observations alone are insufficient for reliable launch dates. The development component recognizes attributable contracts and trial supply where actual transactions occur. It does not capitalize the entire value of possible future milestones into current market revenue.

Operational constraints such as viral handling and image-guided access can delay 2026 adoption. Superficial melanoma injections can occur in specialist clinics, whereas deeper tumors may require interventional imaging, endoscopy or coordinated surgery and radiotherapy. Viral products also involve preparation, handling, monitoring and repeat visits. The economic forecast separates medicine supply from procedure services and avoids assigning the full value of systemic nivolumab or pembrolizumab to the local therapy. Investment in qualified centers supports adoption, but reimbursement and biosafety requirements can slow implementation.

Coverage includes a defined 2025 revenue base, 2026 estimate, 2034 forecast, exclusive segmentation, five-region analysis, clinical and regulatory evidence, development-stage companies and a signed impact reconciliation.